533 related articles for article (PubMed ID: 22536569)
1. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
Ou SH
Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
[TBL] [Abstract][Full Text] [Related]
6. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
7. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
Dikopf A; Wood K; Salgia R
Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
10. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
12. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
14. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
Cameron L; Solomon B
Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
[TBL] [Abstract][Full Text] [Related]
15. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
16. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
19. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
Ou SH; Bartlett CH; Mino-Kenudson M; Cui J; Iafrate AJ
Oncologist; 2012; 17(11):1351-75. PubMed ID: 22989574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
